In summary, considering the BCR as tumor-specific cell surface marker which is also distinct from the BCRs displayed on non-malignant B cells, we developed a novel strategy for a custom-tailored targeted therapy to induce death in lymphoma B cells in a time efficient and inexpensive manner. The gene discussed is BCR; the disease is neoplasm.